Description
+ Include: 8 videos + 14 pdfs, size: 19.5 GB
+ Target Audience: pathologists, hematopathologists
+ Sample video: contact me for sample video
+ Information:
Original release date: December 19, 2024
Course Description
The practice of hematopathology diagnostics in the modern era is a dynamic and challenging field, especially for general pathologists, junior faculty, and trainees. In addition to the ever-expanding landscape of ancillary studies, especially molecular and cytogenetic studies, two new classification schemes arrived on the scene in 2022. The new International Consensus Classification and the updated WHO 5th edition classification, offer similar but not identical frameworks for clinical diagnostic hematopathology. Additionally, distinction of reactive from neoplastic entities remains a continuous challenge in both bone marrow and lymphoid tissue. Finally, clinical hematology, which impacts the treatment of our patients, is also a continuously evolving field and it is essential to understand how to best provide diagnoses that are updated, accurate, and accessible to our clinical colleagues. This course will seek to highlight diagnostic issues raised by these recent advances through an interactive case-based format. These cases will illustrate how to interpret and apply morphologic criteria in the diagnosis of hematologic neoplasms, especially areas of ambiguity or disagreement within the two classifications. It will also highlight how to avoid diagnosing malignancy in benign mimics, and how apply ancillary testing in concert with the morphology, particularly when there are discordant or unexpected results.
Target Audience
General pathologists who diagnose bone marrow and lymphoid lesions, practicing hematopathologists and advanced hematopathology trainees.
Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Apply current classification criteria to the diagnosis of hematologic neoplasms, both lymphoid and myeloid.
- Recognize pitfalls and challenges of common and esoteric hematologic disorders.
- Utilize ancillary testing in an appropriate and cost-effective manner in the diagnosis of benign and malignant entities in bone marrow and tissue-based hematopathology.
+ Topics:
Aggressive B-Cell Lymphomas-Classification Updates and Diagnostic Dilemmas – Rebecca King, MD Handout.pdf
Aggressive B-Cell Lymphomas-Classification Updates and Diagnostic Dilemmas – Rebecca King, MD Slide.pdf
Aggressive B-Cell Lymphomas-Classification Updates and Diagnostic Dilemmas – Rebecca King, MD.ts
Approach to the Fibrotic Bone Marrow Disease – Megan Nakashima, MD Handout.pdf
Approach to the Fibrotic Bone Marrow Disease – Megan Nakashima, MD.ts
Challenges in the Diagnosis of Small Low Grade B-Cell Lymphomas – Rebecca King, MD Handout.pdf
Challenges in the Diagnosis of Small Low Grade B-Cell Lymphomas – Rebecca King, MD Slide.pdf
Challenges in the Diagnosis of Small Low Grade B-Cell Lymphomas – Rebecca King, MD.ts
Clonal Cytopenias, Myelodysplastic Syndrome (MDS), and Related Entities – Katherine Calvo, MD, PhD Handout.pdf
Clonal Cytopenias, Myelodysplastic Syndrome (MDS), and Related Entities – Katherine Calvo, MD, PhD Slide.pdf
Clonal Cytopenias, Myelodysplastic Syndrome (MDS), and Related Entities – Katherine Calvo, MD, PhD.ts
Extranodal Lymphoproliferations – James Cook, MD, PhD Handout.pdf
Extranodal Lymphoproliferations – James Cook, MD, PhD.ts
Germline Predisposition in Myeloid Neoplasia, Bone Marrow Failure, and Pediatric Myelodysplasia – Katherine Calvo, MD, PhD Handout.pdf
Germline Predisposition in Myeloid Neoplasia, Bone Marrow Failure, and Pediatric Myelodysplasia – Katherine Calvo, MD, PhD Slide.pdf
Germline Predisposition in Myeloid Neoplasia, Bone Marrow Failure, and Pediatric Myelodysplasia – Katherine Calvo, MD, PhD.ts
Myeloma and Other Immunosecretory Disease – Megan Nakashima, MD Handout.pdf
Myeloma and Other Immunosecretory Disease – Megan Nakashima, MD Slide.pdf
Myeloma and Other Immunosecretory Disease – Megan Nakashima, MD.ts
T-Cell Lymphproliferations and the Utility of NGS – James Cook, MD, PhD Handout.pdf
T-Cell Lymphproliferations and the Utility of NGS – James Cook, MD, PhD Slide.pdf
T-Cell Lymphproliferations and the Utility of NGS – James Cook, MD, PhD.ts
Reviews
There are no reviews yet.